What is eMed?
Founded in 2020, eMed operates at the intersection of telehealth and quantitative medicine. The company has developed a sophisticated digital platform that facilitates at-home health testing, supervised by certified guides to ensure clinical accuracy and patient safety. By shifting the point-of-care from traditional brick-and-mortar facilities to the home environment, eMed is addressing systemic inefficiencies in the healthcare delivery model. Its platform is designed to provide rapid, affordable, and accessible diagnostic solutions, which are essential for modernizing public health responses and improving individual health outcomes through data-driven interventions.
How much funding has eMed raised?
eMed has raised a total of $200M across 1 funding round:
Series A
$200M
Series A (2026): $200M with participation from Aon
Key Investors in eMed
Aon
Aon is a global professional services firm providing risk management, insurance brokerage, and human capital consulting, with a deep focus on structuring and administering complex health and benefits programs for large-scale enterprises.
What's next for eMed?
With this major strategic investment, eMed is poised to enter a phase of aggressive operational scaling. The company is expected to leverage these funds to enhance its technological stack, broaden its diagnostic test portfolio, and strengthen its network of certified guides. As the healthcare industry continues to prioritize remote and decentralized care models, eMed is strategically positioned to capture significant market share. Future growth will likely focus on integrating its platform with broader enterprise health systems, thereby solidifying its role as a critical infrastructure provider in the evolving landscape of digital health and preventative medicine.
See full eMed company page
